Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Autotelicbio
Primary Objectives:
* To demonstrate superiority of 12-week co-administration of ATB-1011 and ATB-1012 in blood pressure control over ATB-1012 monotherapy
* To demonstrate superiority of 12-week co-administration of ATB-1011 and ATB-1012 in diabetes control over ATB-1011 monotherapy
Age
19–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Those with Primary Hypertension and Type II Diabetes Mellitus (DM)
Those who have been given adequate explanation about the purpose and the details of the clinical trial and have given voluntary, written informed consent
Those who have not taken any antihypertensive agents for ≥2 weeks prior to randomization.
Those who have not taken any oral hypoglycemic agents, except for same dose of metformin (≥1000 mg/day), for ≥8 weeks prior to randomization
You may not be if
Those with reference arm mean sitting diastolic blood pressure (MSDBP) ≥110 mmHg at screening or at randomization
Those with differences of systolic blood pressure (SBP) ≥ 20 mmHg and diastolic blood pressure (DBP) ≥ 10 mmHg between arms measured 3 consecutive times with ≥2 minutes between each measurement at screening
Those with a history of alcohol or substance abuse
Those who are pregnant or nursing
Those who have received other clinical trial drugs within 12 weeks prior to screening
Those who are deemed ineligible to participate in the clinical trial based on the medical opinion of the investigator